The updated AI-enabled software reportedly facilitates enhanced MRI imaging of the brain, abdomen, and pelvis.
The Food and Drug Administration (FDA) has granted 510(k) clearance for updated artificial intelligence (AI) software that bolsters image quality on magnetic resonance imaging (MRI) scans.
Emphasizing noise reduction without sacrificing diagnostic integrity, the Ezra Flash AI software bolsters the quality of MRI scans of the brain, abdomen and pelvis, according to Ezra, the manufacturer of Ezra Flash AI.
In addition to enhanced neuroimaging, the newly FDA-cleared updates for the Ezra Flash AI software may provide visualization with abdominal and pelvic MRI scans, according to Ezra, the developer of the software. (Images courtesy of Ezra.)
The company maintained that the enhanced image quality obtained with Ezra Flash AI will provide greater clarity in MRI interpretation and precise analysis to facilitate a more timely diagnosis.
"The FDA clearance of Ezra Flash represents a significant advancement in making AI-powered cancer screening more accessible," said Daniel K. Sodickson, M.D., Ph.D, the chief scientific advisor at Ezra and chief of innovation in the Department of Radiology at the New York University Grossman School of Medicine. "This technology enables faster, more accurate early cancer detection, ultimately giving patients and their doctors clearer insights for making informed healthcare decisions."
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.